GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, provided an update on its Nasdaq listing status and reaffirmed its commitment to key strategic priorities. The company requested a hearing before the Nasdaq Hearings Panel to appeal the delisting determination received on August 27, 2026, related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and has stayed any suspension or delisting action, allowing GeoVax’s common stock to continue trading on The Nasdaq Capital Market under the symbol “GOVX” at least through the hearing and any extension period granted by the Panel.
David Dodd, Chairman and CEO, stated, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution.” He added that the company continues to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue manufacturing and global preparedness capabilities, and engage potential strategic partners.
GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings.
The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness. For more information, visit www.geovax.com.
This news matters because GeoVax’s ability to maintain its Nasdaq listing is critical for investor confidence and access to capital, which are essential for funding its costly clinical trials. The appeal and the scheduled hearing provide a temporary reprieve, but the outcome will significantly impact the company’s near-term financial stability and its capacity to advance GEO-MVA and Gedeptin. The reaffirmation of strategic priorities underscores that despite the listing challenge, GeoVax remains focused on addressing global health threats like mpox and smallpox, as well as advancing cancer immunotherapy. The emphasis on vaccine supply resilience and biodefense preparedness aligns with growing global concerns, positioning GeoVax’s programs as potentially vital for public health. However, the forward-looking statements highlight inherent risks, including the need for additional capital and regulatory approvals, which could affect the company’s future. Investors and stakeholders will be watching the October hearing closely, as a positive resolution could stabilize the stock and allow GeoVax to continue its mission.
